HUNAN ER-KANG PHARHH

HUNAN ER-KANG PHAR

4.34CNYD
+0.58+15.43%
At close at 08:15 GMT
CNY
No trades
See on Supercharts

300267 fundamentals

Key facts

Market capitalization‪7.76 B‬CNY
Basic EPS (TTM)−0.17CNY
Founded2003
Employees (FY)‪1.45 K‬
CEOQingrong Sun
About

Hunan Er-Kang Pharmaceutical Co., Ltd. engages in the research and development, production and sale of pharmaceutical products. It offers pharmaceutical excipients, active pharmaceutical ingredients (API) and pharmaceutical preparation. The pharmaceutical excipients produce glycerol, medicinal alcohol, propylene glycol, medicinal sodium hydroxide and medical sucrose. The API includes glycerol, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium and calamine powder. The pharmaceutical preparation provides sulbenicillin sodium injection and compound liquorice tablets. The company was founded by Fang Wen Shuai on October 22, 2003 and is headquartered in Changsha, China.

Ownership
‪‪2.06 B‬‬
Free Float shares
‪‪1.30 B‬‬ (62.87%)
Closely held shares
‪‪765.76 M‬‬ (37.13%)
Free Float shares
‪‪1.30 B‬‬ (62.87%)
Closely held shares
‪‪765.76 M‬‬ (37.13%)
Capital structure
Market cap
‪‪7.76 B‬‬
Debt
‪‪422.04 M‬‬
Minority interest
‪‪−49.48 M‬‬
Cash & equivalents
‪‪706.06 M‬‬
Enterprise value
‪‪7.42 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪7.76 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
6.45x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
6.45x
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪1.50‬
‪3.00‬
‪4.50‬
‪6.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−135%‬
‪−90%‬
‪−45%‬
‪0%‬
‪45%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−400.00 M‬‬
‪‪−200.00 M‬‬
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪90.00 M‬‬
‪‪180.00 M‬‬
‪‪270.00 M‬‬
‪‪360.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪90.00 M‬‬
‪‪180.00 M‬‬
‪‪270.00 M‬‬
‪‪360.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Auxiliary Material
Finished Medicine
Raw Materials
Other
New Energy Materials
By country
Period: 2024
China
Overseas

Dividends

Dividend yield, history and sustainability

Dividend summary
0.00%
Payout ratio (TTM)
Dividend yield TTM
0.00%
Last payment
Last ex-date
Last pay date
Dividend history
‪0.0%‬
‪0.3%‬
‪0.6%‬
‪0.9%‬
‪1.2%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.01‬
‪0.03‬
‪0.04‬
‪0.06‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−250.00 M‬‬
‪0.00‬
‪‪250.00 M‬‬
‪‪500.00 M‬‬
‪‪750.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪900.00 M‬‬
‪‪1.80 B‬‬
‪‪2.70 B‬‬
‪‪3.60 B‬‬
Assets
Liabilities